Suppr超能文献

肺腺癌中的微小染色体维持蛋白:临床意义和治疗靶点。

Minichromosome maintenance proteins in lung adenocarcinoma: Clinical significance and therapeutic targets.

机构信息

Department of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Japan.

Department of Functional Genomics, Chiba University Graduate School of Medicine, Japan.

出版信息

FEBS Open Bio. 2023 Sep;13(9):1737-1755. doi: 10.1002/2211-5463.13681. Epub 2023 Aug 7.

Abstract

Lung cancer is the most common cause of cancer-related death worldwide, accounting for 1.8 million deaths annually. Analysis of The Cancer Genome Atlas data showed that all members of the minichromosome maintenance (MCM) family (hexamers involved in DNA replication: MCM2-MCM7) were upregulated in lung adenocarcinoma (LUAD) tissues. High expression of MCM4 (P = 0.0032), MCM5 (P = 0.0032), and MCM7 (P = 0.0110) significantly predicted 5-year survival rates in patients with LUAD. Simurosertib (TAK-931) significantly suppressed the proliferation of LUAD cells by inhibiting cell division cycle 7-mediated MCM2 phosphorylation. This finding suggested that MCM2 might be a therapeutic target for LUAD. Moreover, analysis of the epigenetic regulation of MCM2 showed that miR-139-3p, miR-378a-5p, and miR-2110 modulated MCM2 expression in LUAD cells. In patients with LUAD, understanding the role of these miRNAs may improve prognoses.

摘要

肺癌是全球癌症相关死亡的最常见原因,每年导致 180 万人死亡。对癌症基因组图谱数据的分析表明,微染色体维持 (MCM) 家族的所有成员(参与 DNA 复制的六聚体:MCM2-MCM7)在肺腺癌 (LUAD) 组织中均上调。MCM4(P=0.0032)、MCM5(P=0.0032)和 MCM7(P=0.0110)的高表达显著预测了 LUAD 患者的 5 年生存率。Simurosertib(TAK-931)通过抑制细胞分裂周期 7 介导的 MCM2 磷酸化显著抑制 LUAD 细胞的增殖。这一发现表明 MCM2 可能是 LUAD 的治疗靶点。此外,对 MCM2 的表观遗传调控分析表明,miR-139-3p、miR-378a-5p 和 miR-2110 调节 LUAD 细胞中的 MCM2 表达。在 LUAD 患者中,了解这些 miRNA 的作用可能会改善预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23e6/10476565/06df5d98674e/FEB4-13-1737-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验